Clinical Compound Bank
Looking to advance your research? Seeking a breakthrough therapy for your patients?
We offer patient ready compounds for novel, clinical and translational research into diseases with significant unmet medical needs. These compounds, which have demonstrated evidence of target coverage and manageable tolerability in humans, provide opportunities for you to explore disease biology, advance medical science and potentially discover novel therapies for patients.
Let’s partner in clinical or translational research
Every scientist involved in medical research knows about the challenges posed by limited resources and expertise, and the hard choices one must make in terms of prioritising research activities.
Interested investigators are invited to:
- Explore our Clinical Table of Compounds and examine the key properties of any compound/mechanism of interest
- Learn the process, criteria, and rough timelines for proposal submission through to full project plan development and final approval
- Submit a short 2-3 page ‘Concept Proposal’.
Additional marketed, biologic and late-stage clinical development compounds are offered via the AstraZeneca Externally Sponsored Scientific Research portal.
Investigator-sponsored clinical projects in progress
studies already completed
Submitting a clinical research proposal
- Select a compound
- Read the ‘Instructions for Authors’
- Generate a brief, non-confidential ‘Concept Proposal’
- Submit your proposal
How to submit a clinical research proposal PDF 82KB
- Decisions (accepted, additional information requested, declined) and reviewer feedback within 8 weeks
- Proposals are judged based on:
- scientific merit, strength and uniqueness of hypothesis
- compelling nature of medical need
- technical feasibility
- probability of a successful patient outcome
- advantage over current standard of care
Instructions for authors PDF 88KB
Full project proposal generation
- Share Investigators' Brochure and important additional information, typically under a bidirectional Confidential Disclosure Agreement
- Discuss and compile details for ‘full’ project proposal and clinical protocol
- Agree milestones, decision points, timelines and responsibilities
- Discuss and identify project funding
Final approval and set-up
- Completion of Collaborative Research or Clinical Trial Agreement
- AstraZeneca supplies formulated compound, matching placebo and cross-referencing permission as well as bridging CMC regulatory documentation for IND filing
- Principle Investigator files an investigator-sponsored IND
Project execution and reporting
- Principle Investigator executes the study
- Regular meetings and reports to discuss progress and enable course revisions as needed
- Final report and manuscript submission within 6 months of study completion
- Generation of data to support follow-on studies and grant applications
- Royalties if project intellectual property (IP) is licensed and commercially successful
A word on Intellectual Property
Addressing Intellectual Property (IP) is key to promoting open innovation. It’s essential that we build mutual trust and reward innovation – this means if one party generates IP, they get rewarded and recognized for it. If we create new IP as a result of our collaboration, then we work out how to share it on a case-by-case basis in a way that works for both parties.
Clinical compounds available
|Compound||Mechanism of action||Originating therapeutic area||Proposal type||CNS Penetrant||Target Class||Original Indication||Route|
|AZD0328||Mechanism of action Nicotinic acetylcholine receptor alpha 7 (α7 nAChR) agonist||Originating therapeutic area CNS||Proposal type Clinical & Preclinical||CNS Penetrant Yes||Target Class Ligand-gated ion channel||Original Indication Cognitive impairment||Route Oral|
|AZD1236||Mechanism of action Matrix metalloproteinase 9 & 12 (MMP9,12) inhibitor||Originating therapeutic area Inflammation||Proposal type Clinical & Preclinical||CNS Penetrant Low||Target Class Enzyme||Original Indication COPD||Route Oral|
|AZD1656||Mechanism of action Glucokinase (GK; hexokinase 4) activator||Originating therapeutic area Metabolic Disease||Proposal type Clinical & Preclinical||CNS Penetrant Low||Target Class Enzyme||Original Indication Diabetes||Route Oral|
|AZD1775||Mechanism of action WEE1 G2 checkpoint kinase inhibitor||Originating therapeutic area Oncology||Proposal type Clinical & Preclinical||CNS Penetrant Unknown||Target Class Kinase||Original Indication Advanced Solid Tumours||Route Oral|
|AZD1981||Mechanism of action Chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2) antagonist [prostaglandin D2 (DP2) receptor antagonist]||Originating therapeutic area Inflammation||Proposal type Clinical & Preclinical||CNS Penetrant Low||Target Class GPCR||Original Indication Asthma, COPD||Route Oral|
|AZD2014||Mechanism of action Mammalian target of rapamycin (mTOR) serine/threonine kinase (dual TORC1 and TORC2) inhibitor||Originating therapeutic area Oncology||Proposal type Clinical & Preclinical||CNS Penetrant Unknown||Target Class Kinase||Original Indication Solid Tumours||Route Oral|
|AZD3241||Mechanism of action Myeloperoxidase (MPO) inhibitor||Originating therapeutic area CNS||Proposal type Clinical & Preclinical||CNS Penetrant Yes||Target Class Enzyme||Original Indication Multiple system atrophy||Route Oral|
|AZD4017||Mechanism of action 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor||Originating therapeutic area Metabolic Disease||Proposal type Clinical & Preclinical||CNS Penetrant Low||Target Class Enzyme||Original Indication Diabetes||Route Oral|
|AZD5069||Mechanism of action Chemokine (C-X-C motif) receptor 2 (CXCR2) antagonist||Originating therapeutic area Inflammation||Proposal type Clinical & Preclinical||CNS Penetrant Unknown||Target Class GPCR||Original Indication Asthma||Route Oral|
|AZD5213||Mechanism of action Histamine receptor 3 (H3) antagonist (inverse agonist)||Originating therapeutic area CNS||Proposal type Clinical & Preclinical||CNS Penetrant Yes||Target Class GPCR||Original Indication Cognition, Daytime Sleepiness, Tourette's||Route Oral|
|AZD5904||Mechanism of action Myeloperoxidase (MPO) inhibitor||Originating therapeutic area Inflammation||Proposal type Clinical & Preclinical||CNS Penetrant Low||Target Class Enzyme||Original Indication COPD, MS||Route Oral|
|AZD7325||Mechanism of action Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAAα2,3) positive modulator||Originating therapeutic area CNS||Proposal type Clinical & Preclinical||CNS Penetrant Yes||Target Class Ligand-gated ion channel||Original Indication General Anxiety Disorder||Route Oral|
|AZD9150||Mechanism of action Signal transducer and activator of transcription 3 (STAT3) antisense||Originating therapeutic area Oncology||Proposal type Clinical & Preclinical||CNS Penetrant Low||Target Class Antisense||Original Indication Hepatocellular Carcinoma||Route IV|
|AZD9668||Mechanism of action Neutrophil elastase (NE) inhibitor||Originating therapeutic area Inflammation||Proposal type Clinical & Preclinical||CNS Penetrant Low||Target Class Enzyme||Original Indication COPD, Cystic Fibrosis||Route Oral|
|AZD9977||Mechanism of action Non-steroidal mineralocorticoid receptor (MR) modulator||Originating therapeutic area Cardiovascular||Proposal type Clinical & Pre-clinical||CNS Penetrant Unknown||Target Class Nuclear Receptor||Original Indication Chronic Kidney Disease||Route Oral|
|Lesogaberan (AZD3355)||Mechanism of action Gamma-aminobutyric acid receptor B (GABAB) agonist||Originating therapeutic area GI||Proposal type Clinical & Preclinical||CNS Penetrant Low||Target Class GPCR||Original Indication GERD||Route Oral|
|Saracatinib (AZD0530)||Mechanism of action Src tyrosine kinase family inhibitor||Originating therapeutic area Oncology||Proposal type Clinical & Preclinical||CNS Penetrant Yes||Target Class Kinase||Original Indication Oncology||Route Oral|
|Zibotentan (ZD4054)||Mechanism of action Endothelin receptor A (ETA) antagonist||Originating therapeutic area Oncology||Proposal type Clinical & Preclinical||CNS Penetrant Low||Target Class GPCR||Original Indication Castration-Resistant Prostate Cancer (CRPC)||Route Oral|
Open Innovation external funding
AstraZeneca collaborates with various government funding bodies and academic institutions to provide funding opportunities for studies that use our compounds.
How do I know that the information I submit to AstraZeneca will remain confidential?
AstraZeneca is committed to the same ethical policy that is practiced during grant and manuscript peer-reviews. We will not use or disclose information you submit, unless you approve in writing, or the information becomes public, is separately received or independently developed.
What are the typical agreement terms?
The AstraZeneca Open Innovation program seeks to utilize terms that facilitate participation, open collaborative brainstorming, problem solving and are consistent with well-established and tested academic-industry agreement structures (e.g., Lambert/miCRA templates in U.K. and NIH/NCATS CRA in U.S.), for example:
- Pre-existing IP remains with the original owner
- New IP follows ownership framework taking into account the contribution of each party and where possible using the well-established academic-industry templates
- Publications are encouraged after allowing AstraZeneca to comment, patent(s) to be filed (if applicable), AstraZeneca confidential information protected
- If the collaboration generates positive findings, AstraZeneca has option to negotiate a license to advance further towards patient benefit and commercialization
- For compounds ‘live’ in development, AstraZeneca minimally receives non-exclusive, royalty-free, fully paid license, with the right to sublicense without limitation, for all purposes for project IP.
In general, Collaborative Research Agreement (CRA) and/or Clinical Trial Agreement (CTA) are/is negotiated for an agreed upon Full Project Proposal/Plan.
1. Ownership of project IP and rewards (e.g., royalties) if positive data found are based on multiple factors including regional/country standards, IP policies and the current development stage/status of the compound.
2. AstraZeneca has at least an option to negotiate a license for project IP.